Furthermore, IL1β treatment could induce icd‐IL1R2 release in a time‐ and dose‐dependent manner in IL1R2‐overexpressing breast cancer cells (Figure 5B,C), and IL1R2 neutralizing antibody pretreatment reversed IL1β induced BMI1 upregulation in breast cancer cells (Figure 5D). Here, IL1R2 is linked to breast carcinoma.